NEW YORK--(BUSINESS WIRE)--(Investrend Research Syndicate) Ernest C. Schlotter, a senior analyst with Investrend affiliate SISM Research and a four star analyst according to StarMine, has reiterated his “Speculative Buy/4” Rating and 12-18 month target price of $2.50 for MIV Therapeutics, Inc. (OTCBB: MIVT) in a Morning Note.
